Press release
mRNA Market Forecasted to Reach USD 128.6 Billion by 2034, Key Players: Moderna & Pfizer/BioNTech
mRNA
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72669
Market Overview
• Market Size 2024: USD 42.5 billion
• Forecast 2034: USD 128.6 billion
• CAGR (2024-2034): 11.6%
Key Highlights:
• COVID-19 established mRNA vaccines as a validated platform, accelerating R&D across therapeutic areas.
• Increasing prevalence of infectious diseases, cancer, and rare disorders drives adoption of mRNA-based therapies.
• Strategic partnerships between pharmaceutical companies, biotech firms, and governments are boosting commercialization.
• Expanding manufacturing capabilities and lipid nanoparticle (LNP) technologies support large-scale production.
While high costs, cold-chain logistics, and regulatory hurdles present challenges, mRNA technology is set to redefine the future of drug development.
Market Segmentation
By Product
• mRNA Vaccines
• mRNA Therapeutics
By Type
• Self-amplifying mRNA (saRNA)
• Non-replicating mRNA
By Application
• Infectious Diseases (COVID-19, Influenza, HIV, Others)
• Cancer Immunotherapy
• Rare Genetic Disorders
• Protein Replacement Therapy
• Other Emerging Applications
By End User
• Hospitals
• Research Institutes
• Biopharmaceutical Companies
• Contract Research Organizations (CROs)
By Delivery Technology
• Lipid Nanoparticles (LNPs)
• Polymer-based Delivery
• Cationic Emulsions
• Other Emerging Technologies
Segmentation Summary:
mRNA vaccines dominate the current market, primarily due to COVID-19. However, therapeutics for oncology and rare diseases are expected to drive the next wave of growth. Self-amplifying mRNA is gaining traction for its efficiency in generating a strong immune response. Lipid nanoparticles remain the leading delivery vehicle, though new delivery systems are under active development to improve stability and tissue targeting.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72669/mrna-market
Regional Analysis
North America
• Largest regional market, accounting for over 45% of global share in 2024.
• Driven by advanced biotech ecosystems, government funding, and the presence of Moderna, Pfizer-BioNTech, and other leaders.
• The U.S. dominates, with strong R&D pipelines and large-scale manufacturing facilities.
Europe
• Strong market presence supported by investments in precision medicine and vaccine manufacturing.
• Germany, France, and the UK lead with research centers and collaborations across academia and industry.
• EU-wide initiatives support innovation in rare disease therapies using mRNA technology.
Asia-Pacific
• Fastest-growing region, projected CAGR of 14.3%.
• China and Japan investing heavily in mRNA infrastructure and clinical development.
• Expanding pharmaceutical manufacturing capabilities and growing healthcare demand are boosting adoption.
Middle East & Africa
• Early adoption stage, but increasing government focus on healthcare innovation and vaccine production.
• Partnerships with global pharmaceutical companies are enabling regional entry.
Latin America
• Brazil and Mexico emerging as key markets with growing biotech investments.
• Moderate growth trajectory supported by vaccination programs and gradual expansion into oncology research.
Regional Summary:
North America and Europe remain leaders due to their established infrastructure and research strength, while Asia-Pacific will emerge as the fastest-growing region by 2034, reshaping the global mRNA landscape.
Market Dynamics
Growth Drivers
• Proven Success of mRNA Vaccines: COVID-19 vaccines validated the platform, creating investor and regulatory confidence.
• Broad Therapeutic Potential: Applications extend across infectious diseases, oncology, and rare genetic disorders.
• Faster Development Timelines: mRNA vaccines and therapeutics can be developed more rapidly than traditional approaches.
• Government and Private Investments: Significant funding supports research, clinical trials, and manufacturing expansion.
Key Challenges
• Cold Chain Requirements: Ultra-low temperature storage and distribution remain logistical hurdles.
• High Development Costs: Complex production and delivery systems increase costs for developers.
• Regulatory Uncertainty: Frameworks for approving new mRNA therapies (beyond vaccines) are still evolving.
• Safety Concerns: Long-term effects of repeated dosing remain under investigation.
Latest Trends
• Oncology Breakthroughs: Growing clinical pipeline for cancer immunotherapies using mRNA.
• Rare Disease Applications: Focus on personalized therapies for small patient populations.
• Next-gen Delivery Systems: Research into polymer-based carriers and cationic emulsions to replace or complement LNPs.
• Global Manufacturing Expansion: Increasing number of mRNA production facilities in Asia-Pacific and Europe.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72669
Competitive Landscape
Key Players
• Moderna, Inc.
• Pfizer, Inc. / BioNTech SE
• CureVac AG
• Translate Bio (Sanofi)
• Arcturus Therapeutics
• Gilead Sciences
• AstraZeneca
• Eli Lilly and Company
• GSK plc
• Novartis AG
• Merck & Co., Inc.
• Daiichi Sankyo
• eTheRNA Immunotherapies
• Strand Therapeutics
• Ethris GmbH
Competitive Summary:
The market is dominated by Moderna and Pfizer-BioNTech, but several new entrants are racing to commercialize therapies beyond COVID-19. Collaborations between biotech innovators and large pharmaceutical companies, such as Sanofi's acquisition of Translate Bio, reflect growing interest in expanding mRNA pipelines. Oncology, rare diseases, and next-gen delivery technologies will define the competitive battleground in the coming decade.
Conclusion
The mRNA market is projected to expand from USD 42.5 billion in 2024 to USD 128.6 billion by 2034, at a strong CAGR of 11.6%. While vaccines continue to dominate revenues, the next decade will see exponential growth in oncology and rare disease therapeutics.
North America and Europe will remain leaders in innovation and infrastructure, but Asia-Pacific is expected to be the fastest-growing hub, driven by government investments, a large patient pool, and expanding biotech capabilities.
Despite challenges in cold chain logistics, regulatory frameworks, and delivery technologies, the market outlook is highly positive. With continued investment and scientific progress, mRNA will remain a cornerstone of modern medicine-redefining how diseases are prevented and treated.
For investors, biopharma companies, and healthcare providers, the decade ahead offers a transformational opportunity to participate in one of the most dynamic segments of the global life sciences industry.
This report is also available in the following languages : Japanese (mRNA市場), Korean (mRNA 시장), Chinese (mRNA市场), French (Marché de l'ARNm), German (mRNA-Markt), and Italian (Mercato dell'mRNA), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72669/mrna-market#request-a-sample
Our More Reports:
Cell Therapy Packaging Market
https://exactitudeconsultancy.com/reports/73531/cell-therapy-packaging-market
Continuous Manufacturing Systems Market
https://exactitudeconsultancy.com/reports/73532/continuous-manufacturing-systems-market
Cold Chain Logistics Market
https://exactitudeconsultancy.com/reports/73533/cold-chain-logistics-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release mRNA Market Forecasted to Reach USD 128.6 Billion by 2034, Key Players: Moderna & Pfizer/BioNTech here
News-ID: 4204274 • Views: …
More Releases from Exactitude Consultancy
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
Anti-CD47 Drugs Market Forecast 2034: USD 9.6 Billion, Key Players: Gilead Scien …
The global oncology landscape is rapidly evolving with breakthroughs in immuno-oncology, one of the most promising being Anti-CD47 drugs. These drugs target the CD47 protein, often referred to as the "don't eat me" signal, which allows cancer cells to evade the immune system. By blocking CD47, these therapies enable macrophages and other immune cells to recognize and destroy cancer cells. This innovation has opened new horizons in cancer treatment, particularly…
More than 100 industry and non-industry players are now assessing the potential …
Introduction
T-cell receptor (TCR) therapy is emerging as one of the most promising forms of adoptive cell therapy in oncology. Unlike CAR-T therapies, which target surface antigens, TCR therapies recognize intracellular tumor antigens presented by major histocompatibility complexes (MHCs), enabling them to target a broader range of cancers, particularly solid tumors.
With cancer remaining the second leading cause of death globally, TCR therapies are being positioned as a next-generation immunotherapy solution. Increasing…
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
